Phase 1 de NCX-4016 pour le cancer du colon par le NCI

Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer

This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) August 2006

Sponsors and Collaborators: Stony Brook University Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00331786


RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of nitric oxide-releasing acetylsalicyclic acid may prevent colorectal cancer.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of nitric oxide-releasing acetylsalicyclic acid in preventing colorectal cancer in patients at high risk of colorectal cancer.


plus d'infos sur : http://clinicaltrials.gov/ct/show/NCT00331786?order=5